RA/QA News Roll: Late October 2023
Here's what's happening at FDA and across the broader life science RA/QA space.
This is our biweekly recap of news and industry happenings curated for our paid subscribers. Our goal is to bring you the headline news and the stories, research, and insights that might be harder to find.
If you haven’t upgraded to a paid subscription yet, you can do so here.
Here are some key items from the past couple of weeks.
FDA Guidances and Related Documents
A guidance document details FDA’s approach to regulating Non-Invasive Remote Monitoring Devices for Patient Monitoring. This policy was initially issued in draft form during the pandemic.
The FDA has submitted two pharmaceutical compounding guidance documents to the White House's Office of Information and Regulatory Affairs for review. These documents pertain to compounding practices involving bulk drug substances.
FDA General
FDA host a webinar on its proposed Laboratory Developed Test (LDT) rule today, Oct. 31. The hour-long webinar will feature a Q&A session “based on questions submitted prior to the webinar.” Questions will not be taken live.